MedTrace Logo

Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.

NCT06729580 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2024-12-11

No results posted yet for this study

Summary

Depression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is the most common diagnosis made for individuals seeking treatment for depression. Although a wide range of treatments have been developed for the treatment of MDD, a significant proportion of patients fail to respond. This study examined the effectiveness of a 10-week behavioural activation intervention for individuals with treatment-resistant depression.

Conditions

  • Treatment Resistant Depression (TRD)

Interventions

BEHAVIORAL

Behavioural Activation

10-week standardized behavioural activation program.

Sponsors & Collaborators

Principal Investigators

  • Michael Sullivan, PhD · McGill University

  • Heather Adams, BSW · Dalhousie University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2023-10-30
Completion
2023-10-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06729580 on ClinicalTrials.gov